PCI 27483

Drug Profile

PCI 27483

Alternative Names: CRA-027483; PCI-27483

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celera Corporation
  • Developer Pharmacyclics
  • Class Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action Factor VIIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pancreatic cancer; Venous thromboembolism

Most Recent Events

  • 26 May 2015 Pharmacyclics has been acquired by AbbVie
  • 04 Jun 2013 Pharmacyclics completes Part A of a 3-part Phase-II trial in Pancreatic cancer in USA (NCT01020006)
  • 11 Oct 2012 Pharmacyclics and Novo Nordisk enter into a strategic license agreement for PCI 27483 in a restricted disease indication outside of oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top